BiotechTube

Etrasimod + Etrasimod + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Jul 29, 2020 → Jun 7, 2023

NCT ID
NCT04556734

About Etrasimod + Etrasimod + Placebo

Etrasimod + Etrasimod + Placebo is a phase 2 stage product being developed by Pfizer for Alopecia Areata. The current trial status is completed. This product is registered under clinical trial identifier NCT04556734. Target conditions include Alopecia Areata.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT05061446Phase 2Completed
NCT04556734Phase 2Completed
NCT04173273Phase 3Terminated

Competing Products

20 competing products in Alopecia Areata

See all competitors
ProductCompanyStageHype Score
BaricitinibEli LillyPhase 2
52
CTP-543Sun PharmaceuticalPhase 2/3
65
CTP-543Sun PharmaceuticalPhase 3
77
Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2/3
65
Baricitinib 4 MG Oral TabletEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
minoxidilJohnson & JohnsonPhase 3
77
5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3
77
Minoxidil + vehicle of 5% Minoxidil topical foamJohnson & JohnsonPhase 2
52
5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3
77
Upadacitinib + Upadacitinib PlaceboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 3
77
Secukinumab + PlaceboNovartisPhase 2
52
DaxdilimabAmgenPhase 2
51
RitlecitinibPfizerPre-clinical
22
LITFULOPfizerPre-clinical
22
RitlecitinibPfizerPre-clinical
22
Ritlecitinib higher dose + Ritlecitinib lower dose + PlaceboPfizerPhase 3
76

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84